SG Americas Securities LLC Has $291,000 Holdings in RxSight, Inc. (NASDAQ:RXST)

SG Americas Securities LLC reduced its position in RxSight, Inc. (NASDAQ:RXST - Free Report) by 90.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,880 shares of the company's stock after selling 56,518 shares during the quarter. SG Americas Securities LLC's holdings in RxSight were worth $291,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Amalgamated Bank boosted its stake in RxSight by 21.3% in the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company's stock valued at $71,000 after buying an additional 207 shares in the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of RxSight by 3.2% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company's stock worth $473,000 after purchasing an additional 242 shares during the last quarter. RiverPark Advisors LLC increased its position in shares of RxSight by 9.6% during the 2nd quarter. RiverPark Advisors LLC now owns 3,379 shares of the company's stock worth $203,000 after purchasing an additional 297 shares in the last quarter. CWM LLC lifted its holdings in RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company's stock valued at $25,000 after purchasing an additional 371 shares during the last quarter. Finally, Arizona State Retirement System boosted its position in RxSight by 5.0% in the second quarter. Arizona State Retirement System now owns 7,765 shares of the company's stock valued at $467,000 after buying an additional 373 shares in the last quarter. Institutional investors and hedge funds own 78.78% of the company's stock.

Insider Buying and Selling at RxSight

In other news, insider Ilya Goldshleger sold 9,000 shares of RxSight stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.25, for a total transaction of $353,250.00. Following the transaction, the insider now directly owns 42,246 shares of the company's stock, valued at $1,658,155.50. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 40,010 shares of company stock valued at $1,905,576. Corporate insiders own 9.36% of the company's stock.

RxSight Trading Up 0.1 %

Shares of NASDAQ:RXST traded up $0.05 during midday trading on Monday, hitting $50.52. The company had a trading volume of 216,390 shares, compared to its average volume of 472,030. The firm has a fifty day simple moving average of $52.09 and a 200 day simple moving average of $53.85. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -40.10 and a beta of 1.20. RxSight, Inc. has a 12 month low of $20.66 and a 12 month high of $66.54.

RxSight (NASDAQ:RXST - Get Free Report) last posted its earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.06. The company had revenue of $34.89 million during the quarter, compared to analyst estimates of $32.33 million. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The company's revenue for the quarter was up 67.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.40) EPS. Equities analysts forecast that RxSight, Inc. will post -0.81 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on RXST. BTIG Research raised their price objective on shares of RxSight from $72.00 to $73.00 and gave the stock a "buy" rating in a report on Monday, July 15th. Stifel Nicolaus cut their price objective on RxSight from $70.00 to $65.00 and set a "buy" rating for the company in a research report on Tuesday, August 6th. Wells Fargo & Company decreased their target price on RxSight from $68.00 to $54.00 and set an "overweight" rating on the stock in a report on Tuesday, August 6th. Oppenheimer reduced their price target on shares of RxSight from $72.00 to $65.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 6th. Finally, Needham & Company LLC restated a "buy" rating and issued a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $60.14.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.